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Abstract
Introduction: Rhabdomyosarcoma (RMS) is the most common soft tissue 
sarcoma in children. This paper aimed to assess the stage, site and treatment 
outcome among RMS patients. Materials and Methods: A  retrospective 
chart review was completed from January 2011 to December 2017 of 
patients that presented to the Department of Paediatric Oncology, Shaukat 
Khanum Memorial Cancer Hospital, Lahore, Pakistan, for the management 
of RMS. Data collection included clinical characteristics, staging, grouping, 
risk stratification, treatment plan, radiotherapy doses and treatment 
outcome. Results: Among 24 subjects, there were a total of 13  (54.2%) 
males and 11 (45.8%) females. The median age at the time of diagnosis was 
2.5 years (range: 0.75–17 years). The majority of the subjects (91.7%) were 
<10 years of age. The median follow-up time was 0.6 years. According to the 
Children’s Oncology Group Classification, 4 (16.7%) subjects were classified 
as low risk, 14 (58.3%) subjects were rated as intermediate risk and 6 (0.25%) 
subjects were stratified as high risk. The most common primary tumour site 
was genitourinary (62.5%) and abdomen/retroperitoneal (20.8%) regions. 
At the time of analysis, nine (37.5%) subjects had died because of the 
disease, 12 (50%) were alive with no evidence of disease and one subject 
had a recurrence of disease and was alive. One subject had abandoned the 
therapy and another was lost to follow-up. Conclusion: Patients with RMS 
presented at the late stages of the disease and it most frequently affected 
genitourinary and abdomen or retroperitoneal areas. Overall, RMS was 
found to have a poor outcome to therapy.
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Introduction
Rhabdomyosarcoma (RMS) is the most common 
soft tissue sarcoma in children, with approximately 
350  cases diagnosed per year in the United 
States.[1] The two major histological types are 
embryonal RMS (ERMS) and alveolar RMS 
(ARMS). There is a disparity between the tumour 
site, histology and clinical behaviour of RMS.[2] 
Paediatric RMS with embryonal histology and a 
location in orbit, head and neck, or genitourinary 
tract has a significantly better prognosis than 
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the tumours with alveolar histology that arise in 
extremities.[3]
Treatment strategies include systemic chemotherapy 
along with surgery and/or radiotherapy as local 
control options. Multimodality treatment has 
resulted in 5-year survival of approximately 67%.[3-5] 
There are limited data on the outcome of RMS from 
developing countries.[6,7] Data from Pakistan are 
scarce with poor outcomes. Bhurgri et al. reported a 
10% 5-year survival in a hundred patients studied.[8] 
Issues contributing to dismal results in this part of 
the world include delay in seeking medical help, 
lack of surgical expertise for local disease control, 
failure to deliver chemotherapy in a timely fashion 
and family compliance.[9]
The purpose of this study was to assess the stage, 
site and treatment outcome among patients 
presenting with RMS in a tertiary care cancer 
hospital in Pakistan.
Materials and Methods
The Institutional Review Board of the hospital 
approved this analysis (EXMPT-19-02-18-01). In 
this study, a 7-year retrospective chart review of 
24 RMS patient records from January 2011 to 
December 2017 who were younger than 18-years 
of age was conducted. All other patients registered 
in the same period were excluded from the analysis. 
Data collection included clinical characteristics, 
staging, grouping, risk stratification, treatment 
plan, radiotherapy doses and outcome of children 
with RMS treated at the Shaukat Khanum Memorial 
Cancer Hospital and Research Centre (SKMCH) 
Lahore, Pakistan.
The study participants were risk-stratified using the 
Children’s Oncology Group (COG) Classification 
[Figure 1].[10,11] The classification depends on both 
the pre-treatment staging system and the surgical 
and histopathologic grouping scheme. It takes into 
consideration the size, site, invasiveness and nodal 
status of the tumour. The grouping system is based 
on the gross and microscopic extent of the residual 
tumour with consideration of regional nodes.
The subjects with embryonal histology were classified 
as low risk (LR). They were further stratified as Stage I 
with a Group I, II, or III, or Stage II with a Group I or II. 
The subjects with non-metastatic alveolar histology 
with Stages I, II, or III and a Groups I, II and III and 
unreacted embryonal tumour with an unfavourable 
site and Stage I or II with a Group III were considered 
to be at intermediate risk (IR). Similarly, all participants 
with Stage IV metastatic tumours with a Group  IV 
were regarded as high risk (HR).
The participants underwent neoadjuvant 
chemotherapy followed by local control through 
surgery and/or radiation therapy (RT). Baseline 
staging and then re-evaluation at week 9 were done 
using computed tomography thorax and magnetic 
resonance imaging of the primary site. Four patients 
had chemotherapy as per the European Soft Tissue 
Sarcoma Study Group (EpSSG) protocol.[12,13] However, 
given the scarcity of bed availability for chemotherapy 
administration, the physicians decided to switch to 
the COG protocols given the ease of administration 
of chemotherapy as an outpatient service.[14,15] 
Chemotherapy agents involved were vincristine, 
actinomycin, cyclophosphamide (VAC), ifosfamide, 
etoposide (IE) and irinotecan. LR participants received 
treatment as per ARST 0331 with 22  weeks of 
therapy.[16] The treatment regimen comprised 
four cycles of VAC, with a total cyclophosphamide 
cumulative dose of 4.8 g/m2, followed by four cycles 
of vincristine and actinomycin (VA) D. The IR subjects 
received therapy as per ARST1431 with 42 weeks of 
VAC alternating with vincristine and irinotecan (VAC/
VI) and radiation starting at 13th week. The HR group 
received treatment as per ARST 0431 with compressed 
cycles of vincristine, doxorubicin, cyclophosphamide 
and IE added to the backbone of VAC/VI.[17,18]
Statistical analysis was done using Statistical Package 
for the Social Sciences version 20 22.0 (SPSS Inc, 
Chicago, IL). The frequencies were calculated for 
quantitative variables using descriptive statistics.
Results
There were a total of 13  (54.2%) males and 
11 (45.8%) females. The median age of diagnosis 
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was 2.5 years with an interquartile range (IQR) of 
2 years (1–3 years). Most of the subjects (n = 22; 
91.7%) were <10 years of age. The median follow-
up time was 7-months with an IQR of 7-months 
(4–11 months). According to the COG classification, 
four (16.7%) subjects were classified as LR, 
14  (58.3%) subjects were considered to be IR 
and six (0.25%) participants were categorized 
as HR. There were two (8.3%) subjects that 
had the alveolar subtype. The primary sites of 
tumour were head and neck area (n = 4, 16.7%), 
genitourinary region (n = 15, 62.5%) and abdomen/
retroperitoneal region (n = 5, 20.8%). Among the 
study participants, two participants had ARMS and 
the rest were diagnosed with ERMS.
At the time of analysis, nine (37.5%) subjects had 
died because of the disease, 12  (50%) subjects 
were alive with no evidence of disease and one 
participant was alive with evidence of disease. One 
participant had abandoned therapy and another 
was lost to follow-up [Table 1]. All subjects (n = 4) 
with LR disease were alive at the time of the last 
follow-up in the clinic. Three of these subjects 
underwent systemic chemotherapy consisting of 
VAC for four cycles, followed by VA for 12 weeks. 
On the contrary, one of these four subjects 
underwent chemotherapy with VAC and VA for 
eight cycles. Three subjects were treated with 
surgery for local control within the participants 
with LR disease, while one subject underwent both 
surgery and RT.
Out of the 14 subjects stratified as IR, seven (50%) 
were alive at the last follow-up visit. For local control 
among the IR group, six subjects had radiation 
and surgery, four participants received radiation 
alone and two subjects had surgery alone. Local 
control could not be achieved (they did not 
undergo surgery or receive RT) in two subjects. 
Both of these participants died. Among the six 
subjects that got both surgery and radiation for 
Figure 1: Rhabdomyosarcoma staging and risk stratification based on the Children’s Oncology Group 
Classification[11] (embryonal rhabdomyosarcoma and alveolar rhabdomyosarcoma)
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local disease, four (66.7%) participants died. Half 
of these died from the progression of the disease, 
while the other half succumbed to therapy-related 
complications. The two subjects that had surgery 
alone were alive and doing well at the time of 
the analysis. All subjects in the IR group received 
chemotherapy. Chemotherapy was provided as 
per the EpSSG-2005 protocol in two subjects, five 
subjects received VAC for 12 cycles followed by a 
combination of VA and VI cycles and seven subjects 
got the VAC and VI for seven cycles each.
Three subjects having HR disease were managed 
by surgery and radiation. At the time of data 
collection, only one of these three subjects was 
disease-free. One participant was from Afghanistan 
who, after undergoing surgery, abandoned the 
therapy due to domestic issues and was lost to the 
follow-up. Out of the two subjects with extensive 
abdominal disease, one was alive with the disease 
after chemotherapy and RT. At the same time, the 
other progressed and died before any local control 
measure. EpSSG-2005 HR protocol was used for 
two subjects, while three got the VAC/VI protocol. 
The most recently admitted child’s chemotherapy 
was as per ARST0431.
Twenty participants were to receive RT according 
to their post-surgical group. Participants with ERMS 
Group I tumours were not given radiation. There 
were no participants with Group II disease in this 
cohort. Nine participants (45%) among those with 
Group  III disease (n = 20; 100%) died before or 
after getting palliative doses of RT for local control. 
Three participants declined RT for local control. 
The remaining eight subjects (40%) got radiation 
of 45 Gray units to genitalia and 50.4 Gray units to 
abdominal-pelvic disease sites.
Discussion
This retrospective review reports a descriptive 
analysis of 24 children treated at a tertiary 
care cancer centre in a lower-middle-income 
country. The study aimed to assess the stage, 
site and treatment outcome among subjects 
with RMS. Most of the tumours were Stage 
3 (54.2%) at presentation. Embryonal histology 
was most prevalent (n = 22, 91.7%). By the last 
follow-up date, out of 24 subjects, 9  (37.5%) 
had died because of disease, 12  (50%) were 
alive with the disease in remission and one was 
alive with evidence of disease. One subject 
abandoned active treatment and another was 
lost to follow-up.
Table 1: Patient characteristics
Characteristics All LR IR HR
Gender
Male 13 2 7 4
Female 11 2 7 2
Age (years)
Median 2.5 3 2 2
Range 0.9-17 0.9-7 1-16 1-17
Residence
Afghanistan 3 0 1 2
Khyber Pakhtunkhwa 10 1 8 1
Punjab 10 3 5 2
Sindh 1 0 0 1
Tumour Site
Favourable 11 4 4 3
Unfavourable 13 0 10 3
Histology
Embryonal 22 4 13 5
Alveolar 2 0 1 1
Group
I 3 2 1 0
II 0 0 0 0
III 20 2 13 5
IV 1 0 0 1
Staging
1 9 4 3 2
2 1 0 1 0
3 13 0 10 3
4 1 0 0 1
Local control
Surgery alone 5 3 2 1a
Radiation alone 5 0 4* 1b
Both 10 1 6** 3c
None 4 0 2*** 1d
*(1 lost follow-up), **(all died), ***(both died), a(abandoned  
therapy), b(alive with disease), c(Two of them died), d(progressed 
and died), LR: Low risk, HR: High risk, IR: Intermediate risk
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Prior studies have identified two critical prognostic 
factors in RMS. These are tumour histology and 
age at the time of diagnosis.[13,14] The mortality 
rates are high in patients with ARMS because of 
its aggressive and metastatic nature. Children 
<10 years of age are likely to have ERMS and those 
10  years or older are likely to have ARMS.[13,14] 
Similarly, older age is associated with a low overall 
survival rate.[13,14] In the present study, there were 
two subjects with ARMS histology. Both subjects 
were not alive at the time of analysis.
A study by Qureshi and Rizvi from Karachi, Pakistan 
found similar results to the present study. Most 
RMS participants had advanced disease and 
the embryonal subtype was the more prevalent 
histopathology.[19] The exact reason for presenting 
at advanced stages of the disease in low-income 
or low-middle income countries was beyond the 
scope of the present study. However, it is likely to be 
associated with a lack of public awareness, denial of 
illness and a fragmented health-care system, which 
creates accessing healthcare facilities difficult. 
Furthermore, there are many obstacles to cancer 
management among the paediatric population in 
developing countries.[9] These include but are not 
limited to delayed diagnosis, cost of travel and 
accommodation to tertiary care centres, family 
education and abandonment.[20]
There are several limitations in the present study. 
First, a small number of subjects were included in 
the study and the duration of follow-up was short. 
Due to this, 5-year and overall survival were not 
calculated. Second, within the small cohort, two 
subjects abandoned the therapy. Monetary and 
infrastructure constraints are key dilemmas for 
families seeking care. Among the lost subjects, 
one was from Afghanistan and the other was 
from Federally Administered Tribal Areas. Third, 
this was a retrospective analysis. Inherently, this 
research design is inclined to recall, reporting and 
observational bias. Nonetheless, in the present 
study, the data were extracted from the electronic 
hospital information system and correlated with 
patient visits to the hospital to reduce the risk of 
recall and reporting bias.
This article, to the best of our knowledge, is the first 
published data of RMS stratification and treatment 
outcomes from Pakistan. To have a favourable 
outcome in RMS, the patients must undergo 
correct stratification. Analysis of our data highlights 
the RMS variations in terms of age and clinical 
presentations in the population of Pakistan. In this 
analysis, the COG classification is used. However, 
current best practices suggest that oncologist 
should incorporate fusion status during the work-
up for stratification.[21] In the present centre, we 
will be incorporating FOXO1 gene rearrangement 
fluorescence in situ hybridization test during the 
work-up of RMS.
Patients with RMS presented at the late stages of the 
disease and it most frequently affected genitourinary 
and abdomen or retroperitoneal areas. Overall, in 
comparison to other Asian countries, children with 
RMS from Pakistan have inferior outcomes.
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